Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin vs Norfloxacin for SBP Prophylaxis
NCT04159870Phase 3Unknown
- Sponsor
- Policlinico Foggia
- Start
- Nov 2019
- Primary completion
- Nov 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of rifaximin in spontaneous bacterial peritonitis (SBP) (2 arms), sponsored by Policlinico Foggia. Primary endpoint: Prevention of Spontaneous Bacterial Peritonitis at 6 months. Status: unknown.
02
Drugs
rifaximin
03
Conditions
spontaneous bacterial peritonitis (SBP)
Beyond the preview
Go deeper on NCT04159870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04159870.